A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects With Active Noninfectious Uveitis
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Filgotinib (Primary) ; Prednisone
- Indications Uveitis
- Focus Therapeutic Use
- Acronyms Humboldt
- Sponsors Gilead Sciences
- 25 Jan 2018 Planned End Date changed from 1 Jun 2021 to 1 Jul 2022.
- 10 Aug 2017 Status changed from not yet recruiting to recruiting.
- 07 Jul 2017 New trial record